Rapid Dose Therapeutics Corp. DOSE
CNSX
| 08/31/2026 | 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -68.51% | -23.57% | 2.89% | 29.06% | 30.24% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -68.51% | -23.57% | 2.89% | 29.06% | 30.24% |
| Cost of Revenue | -72.74% | -28.62% | 13.79% | 47.92% | 57.51% |
| Gross Profit | -65.20% | -18.52% | -8.63% | 12.93% | 14.57% |
| SG&A Expenses | -33.55% | -44.72% | -60.60% | -29.37% | -31.19% |
| Depreciation & Amortization | -14.00% | -7.98% | 105.76% | 159.14% | 168.66% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -40.48% | -35.40% | -43.24% | -12.68% | -11.63% |
| Operating Income | 5.71% | 53.75% | 66.20% | 33.28% | 36.81% |
| Income Before Tax | 5.50% | 28.77% | 56.65% | 17.64% | 25.06% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 5.50% | 28.77% | 56.65% | 17.64% | 25.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.50% | 28.77% | 56.65% | 17.64% | 25.06% |
| EBIT | 5.71% | 53.75% | 66.20% | 33.28% | 36.81% |
| EBITDA | 4.54% | 46.68% | 68.68% | 33.25% | 37.93% |
| EPS Basic | 8.70% | 30.77% | 60.22% | 22.50% | 29.23% |
| Normalized Basic EPS | 10.34% | 29.17% | 60.34% | 22.00% | 29.27% |
| EPS Diluted | 8.70% | 30.77% | 60.22% | 22.50% | 29.23% |
| Normalized Diluted EPS | 10.34% | 29.17% | 60.34% | 22.00% | 29.27% |
| Average Basic Shares Outstanding | 3.55% | 3.78% | 8.76% | 6.04% | 6.71% |
| Average Diluted Shares Outstanding | 3.55% | 3.78% | 8.76% | 6.04% | 6.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |